#1K lumiraDx™ Transforming Community-based Healthcare March 2023 Copyright © 2023 LumiraDx Ltd. All Rights Reserved, Worldwide. *#2Disclaimer FORWARD-LOOKING STATEMENTS All statements other than statements of historical facts contained in this presentation are forward-looking statements. Forward-looking statements may generally be identified by the use of words such as "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect," "should," "would," "plan," "project," "forecast," "predict," "potential," "seem," "seek," "future," "outlook," "target" or other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding estimates and forecasts of other financial and performance metrics, projections of market opportunity and market share, our future results of operations and financial position, business strategy, the Platform, other products, tests, ongoing and planned preclinical studies and clinical trials, regulatory submissions and approvals, research and development costs, timing and likelihood of success, as well as plans and objectives of management for future operations. These statements are based on various assumptions, whether or not identified in this presentation, and on the current expectations of the management of LumiraDx Limited ("LumiraDx" or the "Company") and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by any investor as a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and may differ from assumptions, and such differences may be material. Many actual events and circumstances are beyond the control of LumiraDx. These forward-looking statements are subject to a number of risks and uncertainties, including our ability to compete in the highly competitive markets in which we operate, and potential adverse effects of this competition; our ability to maintain revenues if our products and services do not achieve and maintain broad market acceptance, or if we are unable to keep pace or adapt to rapidly changing technology, evolving industry standards and changing regulatory environments; uncertainty, downturns and changes in the markets we serve; our expectations regarding the size of the POC market for the Platform, the size of the various addressable markets for certain tests and our ability to penetrate such markets by driving the conversion of healthcare providers' testing needs onto the Platform; our commercialization strategy, including our plans to initially focus our sales efforts on large healthcare systems, government organizations and national pharmacy chains that want to deploy comprehensive POC testing across their networks, our strategy on the commercialization of our current and future assays and our ability to launch and obtain regulatory approval for new tests; our ability to increase the installed base of our Instruments; our ability to repay or service our debt obligations and meet the financial covenants related to such debt obligations; our belief that we will be able to drive commercialization of the Platform through the launch of our SARS-CoV-2 antigen and SARS-CoV-2 antibody tests; the willingness of healthcare providers to use a POC system over central lab systems and the rate of adoption of the Platform by healthcare providers and other users; the scalability and commercial viability of our manufacturing methods and processes, especially in light of the anticipated demand for the Platform and our minimum commitments to supply the Instrument and test strips in a timely fashion; our ability to maintain our current relationships, or enter into new relationships, with diagnostics or research and development companies, third party manufacturers and commercial distribution collaborators; our ability to effectively manage our anticipated growth; our ability to rapidly develop and commercialize diagnostics tests that are accurate and cost-effective; the timing, progress and results of our diagnostic tests, including statements regarding launch plans and commercialization plans for such tests, all which may be delayed by or halted due to a number of factors, including the impact of the COVID-19 pandemic and the end of the COVID-19 pandemic; the timing, scope or likelihood of regulatory submissions, filings, approvals, authorizations, certifications, clinical trials or clearances; the pricing, coverage and reimbursement of the Instrument and tests, if approved; our ability to enforce our intellectual property rights and to operate our business without infringing, misappropriating or otherwise violating the intellectual property rights and proprietary technology of third parties; developments and projections relating to our competitors and our industry; our ability to attract, motivate and retain qualified employees, including members of our senior management team; the effects of the COVID-19 pandemic, including mitigation efforts and economic effects, on any of the foregoing or other aspects of our business or operations; social, economic, and labor instability in the countries in which we or the third parties with whom we engage operate, including any impact of the current conflict between Russia and Ukraine; our expectations regarding the time during which we will be an emerging growth company under the JOBS Act and a foreign private issuer; the future trading price of our common shares and impact of securities analysts' reports on these prices; our ability to fully derive anticipated benefits from existing or future acquisitions, joint ventures, investments or dispositions; exchange rate fluctuations and volatility in global currency markets; changes in interest rates, inflation rates and global and domestic market conditions; potential adverse tax consequences resulting from the international scope of our operations, corporate structure and financing structure; U.S. tax legislation enacted in 2017, which could materially adversely affect our financial condition, results of operations and cash flows; increased risks resulting from our international perations and expectations of future expansion of such operations; our ability to comply with various trade restrictions, such as sanctions and port controls, resulting from our international operations; government and agency demand for our products and services and our ability to comply with government contracting regulations; our ability to operate in a litigious environment; and those factors discussed under the header "Risk Factors" in the Annual Report on Form 20-F filed by LumiraDx with the Securities and Exchange Commission, or SEC, on April 13, 2022, in the Form 6-K filed by LumiraDx with the SEC on August 16, 2022, and in other filings made by LumiraDx with the SEC. If any of these risks materialize or LumiraDx's assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that LumiraDx presently knows or that LumiraDx currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect LumiraDx's expectations, plans or forecasts of future events and views as of the date of this presentation. LumiraDx anticipates that subsequent events and developments will cause LumiraDx's assessments to change. However, while LumiraDx may elect to update these forward-looking statements at some point in the future, LumiraDx specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing LumiraDx's assessments as of any date subsequent to the date of this presentation. Accordingly, undue reliance should not be placed upon the forward-looking statements. LumiraDx has no obligation to update this presentation. INDUSTRY AND MARKET DATA This presentation includes statistical and other industry and market data that we obtained from industry publications and research, surveys and studies conducted by third parties as well as our own estimates of potential market opportunities. Industry publications and third-party research, surveys and studies generally indicate that their information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information. LumiraDx believes that these third-party sources and estimates are reliable, but has not independently verified them. LumiraDx's estimates of the potential market opportunities for its Platform include several key assumptions based on industry knowledge, industry publications, third-party research and other surveys, which may be based on a small sample size and may fail to accurately reflect market opportunities. While LumiraDx believes that its own internal assumptions are reasonable, no independent source has verified such assumptions. The industry in which LumiraDx operates is subject to a high degree of uncertainty and risk due to a variety of important factors that could cause results to differ materially from those expressed in the estimates made by third parties and by LumiraDx. lumiraDx™ Copyright © 2023 LumiraDx Ltd. All Rights Reserved, Worldwide. 2#3Financial Updates • Continued progress on strategic discussions with industry partners to accelerate the business plan, with both additional capital and strategic collaborations under consideration. o Modified debt agreement with senior lender to waive certain financial covenants until June 30, 2023, as strategic discussions progress: Form 6-K filed with the SEC on February 22, 2023 > https://investors.lumiradx.com/node/7321/html lumiraDx™ Copyright © 2023 LumiraDx Ltd. All Rights Reserved, Worldwide. 3#4LumiraDx Today: Transforming Community-based Healthcare Next Generation POC(¹) Diagnostic Company Large Installed Base with Global Commercial Reach Manufacturing Designed for Scale Broad Menu and Pipeline of Diagnostic Tests Experienced Management Team lumiraDx™ Addressing the current limitations of legacy POC systems by bringing lab-comparable performance to the POC in minutes, a broad menu of tests on a single instrument, and a low cost of ownership 25,000+ instruments shipped to 105 countries across primary care, pharmacy, hospital emergency departments, global health, and other settings All current and future POC tests are developed on common strip design, enabling flexible, automated and low-cost manufacturing on a single line. Current manufacturing capacity of 28 million test strips per month Regulatory clearance for 12 tests for use on our Platform, with global TAM of $5B+ (excluding COVID). (2) 50+ assays in three-year roadmap Fourth POC company for founding team. Management team has a successful track record of diagnostic innovation and building / scaling companies in POC (1) "POC" means point of care. (2) Global Total Addressable Market ("TAM"): We estimate each test based on our current assumptions, including (a) the existing market sizes, (b) central lab market that could move to POC; and (c) expansion of diagnostic testing. Copyright © 2023 LumiraDx Ltd. All Rights Reserved, Worldwide.#5Patient visits Point-of-care (GP, Pharmacy, ER) Sample(s) collected lumiraDx™ Healthcare Systems Need Enhanced Access to Diagnostic Testing Sample packed for transport Sample shipped to central lab Test Performed at Central Lab Lab processes sample o Sample Processed by POC instrument Results verified Up to ~1 Week from Collection to Results ID 6. 2 Test Performed at POC Clinician receives Patient receives Copyright © 2023 LumiraDx Ltd. All Rights Reserved, Worldwide. results results "I' Patient receives results Short time between Collection to Results → Enables Faster and more Effective Care * Extended time to diagnosis and treatment selection * Significant logistic requirements * Higher cost to healthcare system Rapid delivery of results and diagnosis Convenient and easily accessible Allows immediate treatment decision (if required) Significant cost efficiencies Improved patient experience 5#6Ron Zwanziger CEO, Co-Founder, Chairman and Director Tom Quinlan General Manager, Health IT lumiraDx™ Dave Scott, Ph.D. Chief Technology Officer, Co-Founder and Director David Walton, D.M.S. Chief Commercial Officer Dorian LeBlanc, C.P.A. CFO and Vice President, Global Operations Leadership Team Jerry McAleer, Ph.D. Chief Scientist, Co-Founder and Director Peter Scheu President, North American Commercial Operations Pooja Pathak Chief Product Officer Nigel Lindner, Ph.D. Chief Innovation Officer Veronique Ameye Deputy Chief Executive Officer and General Counsel Copyright © 2023 LumiraDx Ltd. All Rights Reserved, Worldwide. inverness (Founders) Abbott Baxter UniPath. SPD Swiss Precision Diagnostics GmbH Management Experience Omnicom Alere (Founders) TM Lilly Thermo Fisher SCIENTIFIC CORNING Unilever FitLinxx. MediSense® (Founders) NOVARTIS BIO RAD Apogent Concateno™ ::DigiTech (O#7Current POC Solutions Have Major Limitations The traditional approach to POC test development has limited scalability and has resulted in ineffective, inefficient and costly solutions X Poor clinical performance in areas of high clinical need X High cost of total ownership X Limited test menu lumiraDx™ 85 Coagulation Respiratory Molecular Copyright © 2023 LumiraDx Ltd. All Rights Reserved, Worldwide. BDS O Respiratory Immunoassay 20x Jo Diabetes, Cardiovascular Diabetes, Inflammation A Cardiac, Blood gas, Metabolic 7#8We Have Developed and Commercialized an Innovative, Disruptive Solution for POC Testing Consolidating multiple POC systems onto a single instrument, the LumiraDx Platform is designed to be a one-stop solution to transform diagnostic testing and health outcomes around the world lumiraDx™ SAMPLE 15:43 15 Sep 2017 General User Patient Test Result History Settings 100% Quality Control Logout lumiraDx Copyright © 2023 LumiraDx Ltd. All Rights Reserved, Worldwide. Lab-comparable performance in minutes Broad menu of tests on a single instrument Low cost of ownership 8#9LumiraDx Platform Simplifies, Scales Down and Integrates Principles Used in Lab Systems Common Transduction Precise Fluidic Control No Sample Matrix Bias Non-Specific Binding Control Calibration Bias Assay Precision lumiraDx™ LumiraDx Platform Fluorescence / electrochemical Piezo bender / test strip bladder Gas wash / liquid-free image Particle coating / anti-hama Calibration to lab standard Materials, process, assay controls Central Lab System Fluorescence / chemiluminescence Syringe pumps Multiple buffer washes Assay design / anti-hama Calibration to lab standard Chemistry, assay controls Copyright © 2023 LumiraDx Ltd. All Rights Reserved, Worldwide. HU D General User Result History Patient Toat Tumira Dx TALLIL Quality Control SARS-CoV-2 & Flu A/B 9#10Our Platform Allows for Multiple Sample Types and Test Technologies on Common Strip Architecture Test Technologies Immunoassay Enzyme Molecular Sample Types Fingerstick blood Venous blood/ Plasma/Serum lumiraDx™ Clinical Chemistry Hematology Electrolytes / Blood Gas Nasal/Nasopharyngeal Throat Swab + Saliva Urine Copyright © 2023 LumiraDx Ltd. All Rights Reserved, Worldwide. INR HAND D III- D-Dimer SARS COV-2 Ab THIN SARS COV-2 Ag 10#11Simple, Common Strip Design Enables Low Cost and Disruptive Market Pricing 0.10 0.10 0.065 0.11 lumiraDx™ 0.30 0.10 500 200 04 0000 Base Price Central Lab Copyright © 2023 LumiraDx Ltd. All Rights Reserved, Worldwide. Testing Prices* 2 - 3x Central Lab LumiraDx POC company estimate 5 - 10x Central Lab Other POC 11#12HU Sample 1 2 Sample Added 3 High Sensitivity at POC Driven by Microfluidic Immunofluorescence Technology Sample and Reagents Actively Mixed ■ in Channels Active Fluidics Move Sample lumiraDx™ 4 Sandwich Assay Binding WWW Assay Binding View Mag Particle Mag Y Fluorescent Latex Latex Magnet 5 Magnetic Field Captures Bound Particles Copyright © 2023 LumiraDx Ltd. All Rights Reserved, Worldwide. 6 04 Sample and Any Unbound Label Removed Using Air یی Magnet 8 Results Displayed Finish JOHN SOLTANTANG M SARS-COM-2A 0 POSITIVE + SARS-CoV-2 Ag Comment Optical Reader Engine Magnet 7 Dry, Clear Fluorescent Signal Measured lumiroDx RESULTS IN MINUTES 12#13We Have Launched a Broad Menu of Tests with Lab Comparable Performance TAM¹ Market² TAM¹ Market² LORE SARS-COM-2 Ag SARS-CoV-2 Ag Test US/EU/JP/BR Lump INR INR Test lumiraDx™ $500M SARS-CoV-2 Ab EU SARS-CoV-2 Ab Test Coagulation Luminox POOL TEST SARS-CoV-2 Ag Pool Test D-Dimer SARS-CoV2 Ag $12B D-Dimer Test $700M EU MORS SARS-CoV-2 Ag Ultra Ti SARS-CoV-2 Ag Ultra Test EU CRP Test POOL TEST Inflammation $300M EU SARS-CoV-2 Ag Ultra SARS-CoV-2 Ag Ultra Pool Test Respiratory HbAlc SARS-COM-2 & Flu A/B SARS-CoV-2 & Flu A/B Test $1.5-3B ummo EU / JP Diabetes HbAlc Test $1.3B EU de SARS-COV 2 & RSV SARS-CoV-2 & RSV Test $200-400M EU Cardiovascular ma NT-proBNP Copyright © 2023 LumiraDx Ltd. All Rights Reserved, Worldwide. NT-proBNP Test $350M EU amira COVID-19 Self-Tast mies apes 2 years I Suminox -- $9B ☐☐☐☐ EU SO TESTS lumiaDx SAS-COV RNA STAR Area Legend d 8.3 Enzyme Molecular $12B/$12B/$1B RNA STAR COVID RNA STAR COVID RNA STAR Complete COVID & Flu RNA STAR Complete Qualitative Immunoassay US / EU Quantitative Immunoassay (1) 2021 Global Total Addressable Market ("TAM"), based on our assumptions, including the (a) existing market sizes, (b) central lab market that could move to the POC, and (c) expansion of diagnostic testing. COVID TAMs difficult to estimate at present, may overlap with each other. (2) Markets with regulatory authorization. Commercial launch of Amira on hold. 13#14Highly Scalable Manufacturing Enables Global Growth Strategy Test strips manufactured on a common platform using a high volume, web-based, automated manufacturing process Platform manufacturing facilities located in Alloa, Stirling and Glasgow, Scotland with total current capacity of over 28 million test strips per month with possibility to expand further Instrument manufactured by Flextronics (a contract manufacturer) at its facility in Althofen, Austria lumiraDx™ Copyright © 2023 LumiraDx Ltd. All Rights Reserved, Worldwide. 14#15Platform Strategy Focused on Improving and Expanding the POC Testing Experience 1 2 3 lumiraDx™ Raise the standard for POC testing performance, speed, access and experience Consolidate multiple POC instruments to a single lab comparable platform Develop comprehensive test menus by disease and care setting Copyright © 2023 LumiraDx Ltd. All Rights Reserved, Worldwide. 15#16Raise the Standard for POC Testing Performance, Speed, Access and Experience High sensitivity and speed: ULTRA product line delivers high sensitivity results for respiratory disease diagnosis, taking test times from 15-30 minutes down to 5 minutes Easy sample collection: Only quantitative fingerstick blood-based tests for D-Dimer and NT- proBNP to aid faster clinical decisions in community settings Built to expand access: Portable system (2.2 lbs, low footprint, battery operated, room temp reagents) and cloud-based connectivity enables centrally managed program in the community lumiraDx™ 500 0 Example: Rule of Venous Thromboembolism with LumiraDx D-Dimer test 0 500 LumiraDx µg/L FEU Copyright © 2023 LumiraDx Ltd. All Rights Reserved, Worldwide. 5000 4500 4000 3500 3000 2000 1500 500- 0 0 500 Method Comparison 1000 1500 2000 2500 3000 9500 4000 4500 5000 bioMérieux Vidas µg/L FEU 100% negative predictive value at the 500 µg/L cut off, when used in combination with a pretest probability score Fingerstick sample, results in 6 minutes Strong correlation with the laboratory reference, in particular around the clinically relevant values of <750 µg/L FEU 16#17LumiraDx NT-proBNP lumiraDx NT-proBNP E MIL *venous blood and plasma also validated lumiraDx™ Sample type: Direct Fingerstick* - No need for phlebotomy - only direct fingerstick NT-proBNP test commercially available today Time to result: 12 minutes Storage at room temperature Strong correlation to gold standard lab system, r=0.97 (Roche cobas Elecsys® proBNP II assay) The innovative LumiraDx NT-proBNP test can transform the diagnosis of heart failure by bringing the first true point of care NT-proBNP test to the community. Copyright © 2023 LumiraDx Ltd. All Rights Reserved, Worldwide.#18Time to Result Sample type Measuring Range Intended Use Menu Storage Registrations *To be extended to 35,000 pg/ml lumiraDx™M LumiraDx umirax NT-proBNP 12 mins Fingerstick capillary, Venous whole blood, plasma 50-9,000 pg/ml* Aid in diagnosis INR, CRP, D-Dimer, Flu, RSV, COVID,HbA1c, Room temperature CE Roche h232 12 mins ▶O Venous whole blood Refrigerated CE J 60-9,000 pg/ml Aid in diagnosis, monitoring and risk stratification TnT, D-dimer, CK-MB, Myoglobin Quidel Triage Trage 20 mins • de a ce Venous whole blood, plasma 20-35,000 pg/ml Aid in the diagnosis and risk stratification D-dimer, BNP, Tnl, Toxicology panel, PLGF, Myoglobin, CK-MB Refrigerated CE (BNP test is FDA CLIA waived) All third-party product, company names and logos are trademarks ™M or registered trademarks and remain the property of their respective holders. Use of them does not imply any affiliation with or endorsement by them. Copyright © 2023 LumiraDx Ltd. All Rights Reserved, Worldwide. Boditech iChroma AFIAS 12 mins Venous whole blood, serum, plasma 10-30,000 pg/ml Aid in diagnosis auf R CE D-dimer, hsCRP, Tnl, Myoglobin, CK-MB, BNP, ST2 Refrigerated#19Unmet Need for High Sensitivity Troponin POC Test with a ~$900M Addressable Market(1) Intended Use Regulatory Authorization LOQ Clinical Sensitivity Reportable Range Sample Size Sample Type Time to Result lumiraDx™ True POC Needs Aids in diagnosis of MI CE Mark, FDA 510K ≤ 2.0 ng/L I Whole blood (2h): 90%+ I 2.0 − 1,000 ng/L 20μL direct fingerstick Capillary WB, venous blood, plasma Lab Reference Abbott Architect STAT hs- Tnl(2) I ≤10 min Aids in diagnosis of MI CE Mark, FDA 510K ≤3.2 ng/L (specification) 1.5-2.9 ng/L (observed) EDTA Plasma (2-4h): 90.9% 3.2 – 50,000 ng/L 210 μL (on-board) 10 μL (manual dilution) Plasma & serum (LiHep, EDTA) POC Example Siemens Atellica VTLi hs- cTnl (2) Aids in diagnosis of MI CE Mark 2.1 ng/L plasma 3.7 ng/L - WB Copyright © 2023 LumiraDx Ltd. All Rights Reserved, Worldwide. Whole blood (2h): 81.3% 2.1 (plasma)/3.7 (WB) - 1,250 ng/L 30-100 μL Capillary WB, venous WB & plasma (LiHep) 18 min (time to first result) (1) Based on our current assumptions, including (a) the existing market sizes, (b) central lab market that could move to POC; and (c) expansion of diagnostic testing. (2) Based on respective company product specifications. 8 min POC Example Triage True hsTnl (²) Aids in diagnosis of MI CE Mark 2.1-3.6 ng/L - plasma 2.8 ng/L - WB EDTA Plasma (2-4h): 91.9% 0.1 – 1,000 ng/L 175 µL Venous WB & plasma (EDTA) 20 min I Key differentiator I 19#20LumiraDx Troponin (pg/mL) 16.0 14.0 12.0 10.0 8.0 6.0 4.0 2.0 0.0 -2.0 lumiraDx™ 2 Feasibility of High Sensitivity Troponin Results at POC LumiraDx Plasma Troponin vs Architect 4 6 8 10 y = 0.9544x + 0.0377 R² = 0.9868 Mean Architect Troponin (pg/mL) 12 14 Copyright © 2023 LumiraDx Ltd. All Rights Reserved, Worldwide. 16 Precision Troponin (pg/mL) 1.1 8.2 19.5 CV % 25 7.4 6.6 N 12 34 36 20#21Key Targets and Workflow ● 98% sensitivity • No culture confirmation Results in 8 minutes, with early call out starting 3 minutes Performance Feasibility Fluorescence (R) 70000 60000 50000 40000 30000 20000 10000 0 0 5 D1 (1:20) Group A Strep 10 Strep A Molecular Program Demonstrates Feasibility to Achieve Target Sensitivity 15 20 Cycles 25 30 lumiraDx™ 35 40 Fluorescence (R) 70000 60000 50000 40000 30000 20000 10000 0 0 D2 (1:200) 5 Group A Strep 10 15 20 Cycles 25 30 35 40 Fluorescence (R) 70000 60000 50000 40000 30000 20000 10000 0 0 Sample Collection & Lysis D3 (1:2000) 5 10 Group A Strep 15 20 Cycles 25 30 35 40 Fluorescence (R) 70000 60000 50000 40000 30000 20000 10000 0 5 Insert Strip & Add Sample D4 (1:20000) Group A Strep 10 Copyright © 2023 LumiraDx Ltd. All Rights Reserved, Worldwide. → 9 → 15 20 Cycles 25 30 35 40 Dilution D1 (1:10¹) D2 (1:10²) D3 (1:10³) D4 (1:104) D5 (1:105) D6 (1:106) D7 (1:107) Amplification LMDX qSTAR 8/8 8/8 8/8 8/8 0/8 0/8 0/8 On market POC MDX 3/3 3/3 3/3 2/3 0/3 0/3 0/3#22TB Molecular Program Demonstrates Feasibility to Develop Swab Based POC Test Key Targets and Workflow Tongue swab sample Results in 20 minutes Access to testing for HIV+ and pediatric populations, currently underserved Performance Feasibility Copy number (cp/rxn) 11 5.6 1.3 0.6 lumiraDx™ No of positives 8/8 8/8 33/38 3/8 % positivity 100 100 87 33 Value Proposition POC TB test has opportunity to increase patients linked to care Number of patients at each step of cascade 5,000,000 4,500,000 4,000,000 3,500,000 3,000,000 2,500,000 2,000,000 1,500,000 1,000,000 500,000 2,840,000 100% Individuals with incident TB 1,938,027 Copyright © 2023 LumiraDx Ltd. All Rights Reserved, Worldwide. 68% 1,629,906 Accessed TB tests 57% 1,417,838 50% 1,221,764 43% Diagnosed with TB Registered in treatment TB Care Cascade in Indian Public Health System B Treatment success 1,049,237 I 37% Recurrence-free survival#23LumiraDx Platform Offers the Benefits of POC Testing with the Accuracy of Laboratory Testing 10 SARS-CoV-2 Ag Ultra SARS-CoV-2 Ag Ultra SARS-COV-2 Ag Ultra lumiraDx™ SARS-CoV-2 Ag Ultra Pool Prep Sample JJ-mixta SARS-CoV2 Ab SARS-CoV-2 Ab SARS-C 1 Minute & RSV SARS-CoV-2 & RSV SA FIU A/B SARS-CoV-2 & Flu A/B HbA1C (4) 900.0 HbA1c D-Dimer D-Dimer Load & Run INR NT-proBNP Copyright © 2023 LumiraDx Ltd. All Rights Reserved, Worldwide. NT-proBNP Report Results 2- 12 Minutes CRP LumiraDx solutions combine common assay types all in one instrument (IA, clin chem, molecular, and enzyme); reduce costs and simplify workflow ✓ A single scalable platform to complete a wide range of popular POC tests Patient receives accurate results in minutes Low-cost of ownership Diagnosis and Treatment Selection 23#24Consolidate Multiple POC Instruments to a Single Lab Comparable Platform INSERT TEST X X X BD Veritor System Coagulation Respiratory Immunoassay lumiraDx™ Diabetes, Inflammation NEAR TERM Able to move most European customers from 3 → 1 Platform with INR, COVID Ag, Flu A/B, RSV, CRP and HbA1c Respiratory Molecular Copyright © 2023 LumiraDx Ltd. All Rights Reserved, Worldwide. 20x Diabetes, Cardiovascular 6 Cardiac, Blood gas, Metabolic 18-24 MONTHS Expect to be able to move most US and European customers 6 → 1 Platform with US authorizations and addition of molecular respiratory, lipids, electrolytes, and cardiac content 24#25400 350 300 250 200 150 100 50 0 Menu Expansion Leading to New Customer Acquisition and Higher Volume per Customer Germany, Austria and Switzerland (DACH) Number of Assays Shipped to Customer Total customers grew from 108 customers in Dec 2021 to 365 customers in Dec 2022 Dec 2021 Mar 2022 lumiraDx™ 1 Jun-22 13 ■4+ Sep-22 Dec-22 1 40% 35% 30% 25% 20% 15% 10% 5% 0% -27% Mar-21 DACH COVID only vs. Multi-Assay Customers Customers with 3+ assays grew from 3% in Dec 2021 to 23% in Dec 2022 w Copyright © 2023 LumiraDx Ltd. All Rights Reserved, Worldwide. 1 ✔ 26% June-21 9% I 1 S 1 1 JP 39% 3% 1 1 Sept-21 % Customers Shipped 3 or more Assays Dec-21 16% Mar-22 14% 13% June-22 Case Study % Covid Only Customers 19% Sept-22 23% 2% Dec-22#26100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% Innovation and Growth in High Sensitivity Respiratory Antigen Testing Q1 2022 Respiratory Revenue Distribution Top 3 Countries - Italy, UK, Japan lumiraDx™ Q2 2022 Q3 2022 Q4 2022 ■COVID AgCOVID Ag Pool COVID Ag UltraCOVID Ag Ultra Pool COVID & Flu Copyright © 2023 LumiraDx Ltd. All Rights Reserved, Worldwide. Launch timelines ● ● ● COVID Ag CE Mark in Aug 2020 COVID Ag PMDA (Japan) in Jan 2021 COVID Ag Pool CE Mark in Jun 2021 COVID & Flu CE Mark in Dec 2021 COVID & Flu PMDA (Japan) in Mar 2022 COVID Ag Ultra and COVID Ag Ultra Pool CE Mark in May 2022#27● ● ● ● Case Study COVID POC Testing Infrastructure Being Redeployed to Strengthen Community Based Care Emergency Department COVID Testing Hubs Outpatient Departments Elective and Emergency Surgery Admissions Hospital Discharge lumiraDx™ UKHSA procured 1500 Instruments NHS Community Diagnostic Cent www Virtual Wards CRP, D-Dimer testing to keep COPD patients out of the hospital ED EMERGENCY Emergency Department D-Dimer testing for fast, accurate rule out of Pulmonary Embolism and Deep Vein Thrombosis Cardiology Department NT-proBNP testing for fast, accurate diagnosis of acute coronary syndrome and heart failure Community Diagnostic Centers D-Dimer, NTproBNP testing in community to reduce ED referrals and congestion Copyright © 2023 LumiraDx Ltd. All Rights Reserved, Worldwide.#28Knowsley Community Respiratory Service - Patient Case Study 65-year-old male - medical history of COPD and hypertension - Contacted the Rapid Response Service complaining of a 3-day history of acute respiratory symptoms - Denied breathlessness, complained of increased chesty cough, expectorating some watery yellow sputum - No chest or pleuritic pain, no haemoptysis, no peripheral oedema, NEWS early warning score = 0 - a low risk patient. - Chest examination scattered crackles to bilateral lower zones Also complaining of congested nose and throat, query if this was a viral illness - LumiraDx CRP Test performed - 124mg/L so patient provided 5-day course of amoxicillin - Follow up visit - patient has not felt improvement and sputum now dark green - LumiraDx CRP Test performed - 160mg/L - change in antibiotic therapy and provided 5-day course of doxycycline - Further home visit 2 days after commencing doxycycline. LumiraDx CRP Test performed - 45mg/L and overall improvement lumiraDx™ Case Study Copyright © 2023 LumiraDx Ltd. All Rights Reserved, Worldwide.#29Respiratory Immunoassay COVID Ag COVID Ab Flu A/B RSV CRP sPneumo Legionella Respiratory Molecular COVID Flu A/B RSV Strep A TB Qual Immunoassay lumiraDx™ Develop Comprehensive Test Menus By Disease and Care Setting Cardiovascular Troponin D-Dimer BNP NT-ProBNP Lipids ALT/AST Na/K/Ca hsCRP Blood Gases Sexual Health Molecular CT/NG Syphilis HCV HBV HIV Quant Immunoassay Coagulation INR D-Dimer Creatinine Sexual Health Immunoassay HIV HCV HBV Syphilis Molecular Diabetes/Kidney Copyright © 2023 LumiraDx Ltd. All Rights Reserved, Worldwide. HbA1c Glucose Creatinine ACR TSH T4 Free T3 Wellness & Other Vitamin D PIGF PSA bHCG Sickle Cell Anemia Enzyme Sepsis Procalcitonin Lactate MRSA Toxicology Opiates Meth/Amphetamines Barbiturates Benzodiazepines Cocaine Methandone * Items marked in bold are the diagnostic tests for which we have obtained regulatory approval, authorization, certification or clearance for use on our Platform. Metabolic/Electrochemical 29#30SARS-CoV-2 Ag Ultra SARS-CoV-2 Ag Ultra 美国 SARS-CoV-2 Ag Ultra SARS-CoV-2 Ag Ultra Pool iriti SARS-CoV2 Ab SARS-CoV-2 Ab Appendix SARS-COM-3 SARS-CoV-2 & RSV J-in-xxx SARS-COVER SARS-CoV-2 & Flu A/B J-inden HbA1c HbA1c D-Dimen D-Dimer INR NT-proBNP NT-proBNP Copyright © 2023 LumiraDx Ltd. All Rights Reserved, Worldwide. Shaina iti H CRP 15:43 15 Sep 2021 Settings General User Patient Test Result History 100% Quality Control Logout lumiraDx#31Point of Care Testing is Being Adopted Worldwide Western World Adoption: A Push Towards Community Care United States A push towards community-based services is at the top of Biden's healthcare agenda with $400bn in Medicaid funding to expand access to home and community based services¹ United Kingdom: NHS is leading the path in Europe In 2019 the NHS outlined its five year plan to move to a new service model for the NHS, setting out five changes required: 1 Boost "out of hospital care" 2 Redesign and reduce pressure on emergency hospital services 3 Deliver more personalised care 4 Digitally enable primary and outpatient care 5 Local NHS organisations to focus on population health To support this the NHS committed £13bn to community pharmacy's confirming their future as an integral part of the NHS² lumiraDx™ Global Health Adoption of POCT(³) POCT improves patient care, especially in re-source limited settings where laboratory infrastructure is poor and patients predominantly live in rural settings O UNAIDS launched the Diagnostics Access Initiative, to ensure increased access to quality diagnosis so people with HIV can be effectively linked to quality treatment services The WHO recognises the importance that quality-assured POCT will play in the success of global health programs O A study assessing the impact of POCT in Global Health disease programs found that: • POCT in HIV resulted in a 20 fold increased uptake and coverage and increased status and awareness from an average of 6% to 20% In tuberculosis, a study found POCT in communities resulted in a 49% increased detection rate of tuberculosis (1) White House Infrastructure Bill 2021 (2) NHS England Long Term Plan 2019 (3) Peter N. Fonjungo, Debrah I. Boeras, Clement Zeh, Heather Alexander, Bharat S. Parekh, John N. Nkengasong, Access and Quality of HIV-Related Point-of-Care Diagnostic Testing in Global Health Programs, Clinical Infectious Diseases Copyright © 2023 LumiraDx Ltd. All Rights Reserved, Worldwide. 31#32lumiraDx™ Copyright © 2023 LumiraDx Ltd. All Rights Reserved, Worldwide.